JP2008500279A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008500279A5 JP2008500279A5 JP2006554230A JP2006554230A JP2008500279A5 JP 2008500279 A5 JP2008500279 A5 JP 2008500279A5 JP 2006554230 A JP2006554230 A JP 2006554230A JP 2006554230 A JP2006554230 A JP 2006554230A JP 2008500279 A5 JP2008500279 A5 JP 2008500279A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cells
- peptide
- cell
- endogenously
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 12
- 238000000034 method Methods 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 239000002609 medium Substances 0.000 claims 3
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 2
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 claims 2
- 239000003540 gamma secretase inhibitor Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 241000699800 Cricetinae Species 0.000 claims 1
- 239000002439 beta secretase inhibitor Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54676404P | 2004-02-23 | 2004-02-23 | |
| US60/546,764 | 2004-02-23 | ||
| PCT/US2005/005198 WO2005082939A2 (en) | 2004-02-23 | 2005-02-17 | Anti-abeta antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008500279A JP2008500279A (ja) | 2008-01-10 |
| JP2008500279A5 true JP2008500279A5 (cg-RX-API-DMAC7.html) | 2008-03-06 |
| JP4851348B2 JP4851348B2 (ja) | 2012-01-11 |
Family
ID=34910810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006554230A Expired - Fee Related JP4851348B2 (ja) | 2004-02-23 | 2005-02-17 | 抗Ａβ抗体 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20070190046A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1720909B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4851348B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR100889430B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1922209B (cg-RX-API-DMAC7.html) |
| AT (1) | ATE534667T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005217596B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0507856A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2556436C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1112162T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1720909T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA009872B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2375627T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL177611A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20064239L (cg-RX-API-DMAC7.html) |
| PL (1) | PL1720909T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1720909E (cg-RX-API-DMAC7.html) |
| SI (1) | SI1720909T1 (cg-RX-API-DMAC7.html) |
| UA (1) | UA93181C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005082939A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
| PT1954718E (pt) | 2005-11-30 | 2014-12-16 | Abbvie Inc | Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos |
| MX358175B (es) | 2005-12-12 | 2018-08-08 | Ac Immune Sa | Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas. |
| US7892544B2 (en) | 2006-07-14 | 2011-02-22 | Ac Immune Sa | Humanized anti-beta-amyloid antibody |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| HRP20140049T1 (hr) | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| HUE034512T2 (en) | 2007-01-05 | 2018-02-28 | Univ Zuerich | A method for providing disease-specific binding molecules and targets |
| WO2008084402A2 (en) | 2007-01-11 | 2008-07-17 | Philipps-Universitaet Marburg | Diagnosis and treatment of alzheimer's and other neurodementing diseases |
| US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| PT2238166E (pt) | 2007-10-05 | 2014-02-11 | Genentech Inc | Utilização do anticorpo anti-amilóide beta em doenças oculares |
| RU2542967C2 (ru) * | 2007-10-05 | 2015-02-27 | Дженентек, Инк. | Применение антитела против амилоида бета при глазных заболеваниях |
| EA201190025A1 (ru) | 2008-11-25 | 2012-12-28 | Байоджен Айдек Ма Инк. | ПРИМЕНЕНИЕ АНТАГОНИСТОВ DR6 И p75 ДЛЯ ПРОМОТИРОВАНИЯ ВЫЖИВАНИЯ КЛЕТОК НЕРВНОЙ СИСТЕМЫ |
| BRPI0923157B1 (pt) | 2008-12-19 | 2021-12-28 | University Of Zürich | Anticorpos anti-alfa-sinucleína e seus fragmentos, seus usos e método de preparação, composição compreendendo-os, bem como kit e métodos para o diagnóstico e monitoramento de uma doença sinucleinopática |
| WO2011060246A2 (en) | 2009-11-12 | 2011-05-19 | Genentech, Inc. | A method of promoting dendritic spine density |
| CN102933601B (zh) | 2010-04-15 | 2016-06-08 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
| MY164579A (en) | 2010-07-30 | 2018-01-15 | Ac Immune Sa | Safe and functional humanized antibodies |
| PL3042917T3 (pl) * | 2010-08-12 | 2018-07-31 | Eli Lilly And Company | Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie |
| MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
| PL2723379T3 (pl) | 2011-06-23 | 2019-05-31 | Biogen Int Neuroscience Gmbh | Cząsteczki wiążące przeciwko alfa-synukleinie |
| US20150209406A1 (en) | 2012-09-07 | 2015-07-30 | Massachusetts Eye And Ear Infirmary | Methods and compositions for regenerating hair cells and/or supporting cells |
| WO2014039781A1 (en) | 2012-09-07 | 2014-03-13 | Massachusetts Eye & Ear Infirmary | Treating hearing loss |
| JP6751344B2 (ja) | 2013-09-13 | 2020-09-02 | ジェネンテック， インコーポレイテッド | 精製された組み換えポリペプチドを含む方法及び組成物 |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| KR102362222B1 (ko) | 2016-05-16 | 2022-02-11 | 더 제너럴 하스피탈 코포레이션 | 폐 상피 공학에서 인간 기도 줄기 세포 |
| WO2018031334A1 (en) * | 2016-08-11 | 2018-02-15 | Eli Lilly And Company | Aminothiazines and their use as bace1 inhibitors |
| AU2018321335B2 (en) | 2017-08-22 | 2025-08-14 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
| TWI843040B (zh) | 2021-01-11 | 2024-05-21 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| JP2025506411A (ja) | 2022-02-03 | 2025-03-11 | イーライ リリー アンド カンパニー | アルツハイマー病の診断及び治療のための局所タウイメージング |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT951466E (pt) | 1996-12-23 | 2009-04-09 | Lilly Co Eli | Compostos cicloalquilo, lactama, lactona e relacionados, composições farmacêuticas compreendendo os mesmos, e métodos para a inibição da libertação do péptido β-amilóide e/ou da sua síntese pela utilização de tais compostos |
| US6518011B1 (en) * | 1999-01-13 | 2003-02-11 | Bristol-Myers Squibb Company | Method for screening compounds to identify beta-amyloid production modulators |
| MXPA02008145A (es) * | 2000-02-24 | 2004-04-05 | Univ Washington | Anticuerpos humanizados que secuestran al peptido beta amiloide. |
| AU2001257022B2 (en) * | 2000-04-13 | 2005-02-03 | Mayo Foundation For Medical Education And Research | Abeta 42 lowering agents |
| TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| ES2437875T3 (es) * | 2001-04-30 | 2014-01-14 | Eli Lilly And Company | Anticuerpos humanizados que reconocen el péptido beta-amiloide |
-
2005
- 2005-02-17 UA UAA200609258A patent/UA93181C2/ru unknown
- 2005-02-17 WO PCT/US2005/005198 patent/WO2005082939A2/en not_active Ceased
- 2005-02-17 PT PT05723280T patent/PT1720909E/pt unknown
- 2005-02-17 DK DK05723280.3T patent/DK1720909T3/da active
- 2005-02-17 JP JP2006554230A patent/JP4851348B2/ja not_active Expired - Fee Related
- 2005-02-17 KR KR1020067016812A patent/KR100889430B1/ko not_active Expired - Fee Related
- 2005-02-17 SI SI200531422T patent/SI1720909T1/sl unknown
- 2005-02-17 US US10/590,411 patent/US20070190046A1/en not_active Abandoned
- 2005-02-17 CA CA2556436A patent/CA2556436C/en not_active Expired - Fee Related
- 2005-02-17 EP EP05723280A patent/EP1720909B1/en not_active Expired - Lifetime
- 2005-02-17 AT AT05723280T patent/ATE534667T1/de active
- 2005-02-17 CN CN2005800056858A patent/CN1922209B/zh not_active Expired - Fee Related
- 2005-02-17 AU AU2005217596A patent/AU2005217596B2/en not_active Ceased
- 2005-02-17 PL PL05723280T patent/PL1720909T3/pl unknown
- 2005-02-17 KR KR1020087031635A patent/KR20090005410A/ko not_active Ceased
- 2005-02-17 ES ES05723280T patent/ES2375627T3/es not_active Expired - Lifetime
- 2005-02-17 EA EA200601545A patent/EA009872B1/ru not_active IP Right Cessation
- 2005-02-17 BR BRPI0507856-3A patent/BRPI0507856A/pt not_active IP Right Cessation
-
2006
- 2006-08-21 IL IL177611A patent/IL177611A/en not_active IP Right Cessation
- 2006-09-19 NO NO20064239A patent/NO20064239L/no not_active Application Discontinuation
-
2011
- 2011-12-21 CY CY20111101276T patent/CY1112162T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008500279A5 (cg-RX-API-DMAC7.html) | ||
| Diller et al. | The role of the extracellular matrix (ECM) in wound healing: a review | |
| Nemmar et al. | In vivo protective effects of nootkatone against particles-induced lung injury caused by diesel exhaust is mediated via the NF-κB pathway | |
| Caballé-Serrano et al. | Tissue response to a porous collagen matrix used for soft tissue augmentation | |
| Hoff et al. | A pronounced inflammatory activity characterizes the early fracture healing phase in immunologically restricted patients | |
| Yamada et al. | Diagnostic cytokines and comparative analysis secreted from exfoliated deciduous teeth, dental pulp, and bone marrow derived mesenchymal stem cells for functional cell-based therapy | |
| EA200600345A1 (ru) | Способ культивирования клеток | |
| Petrini et al. | Influence of nano, micro, and macro topography of dental implant surfaces on human gingival fibroblasts | |
| Ghinassi et al. | Gingival response to dental implant: comparison study on the effects of new nanopored laser-treated vs. traditional healing abutments | |
| Bateman et al. | Airway epithelium senescence as a driving mechanism in COPD pathogenesis | |
| Chu et al. | Fibroblast Yap/Taz signaling in extracellular matrix homeostasis and tissue fibrosis | |
| Loukelis et al. | Kappa-carrageenan/chitosan/gelatin scaffolds provide a biomimetic microenvironment for dentin-pulp regeneration | |
| Zhou et al. | Fabrication of fibrin/polyvinyl alcohol scaffolds for skin tissue engineering via emulsion templating | |
| Zeissig et al. | Tumour dissemination in multiple myeloma disease progression and relapse: a potential therapeutic target in high-risk myeloma | |
| Shimizu et al. | Observation of chronic graft-versus-host disease mouse model cornea with in vivo confocal microscopy | |
| Haas et al. | Recovery of altered diabetic myofibroblast heterogeneity and gene expression are associated with CD301b+ macrophages | |
| DE60319599T8 (de) | Verfahren zur differenzierung einer mesenchym-stammzelle zu einer nervenzelle sowie die nervenzelle enthaltende pharmazeutische zusammensetzung gegen eine neurodegenerative krankheit | |
| Clemens et al. | Understanding antibody responses in early life: baby steps towards developing an effective influenza vaccine | |
| Ishikawa et al. | The role of lactic acid on wound healing, cell growth, cell cycle kinetics, and gene expression of cultured junctional epithelium cells in the pathophysiology of periodontal disease | |
| DE602005001688D1 (de) | Aufbereitung von Aldesleukin zur pharmazeutischen Verwendung | |
| Kim et al. | Identifying stabilin-1 and stabilin-2 double knockouts in reproduction and placentation: a descriptive study | |
| Wang et al. | A deep view of the biological property of interleukin-33 and its dysfunction in the gut | |
| Dong et al. | Cytotoxicity Induced by Black Phosphorus nanosheets in Vascular endothelial cells via oxidative stress and apoptosis activation | |
| Chou et al. | Secretome of hypoxic endothelial cells stimulates bone marrow-derived mesenchymal stem cells to enhance alternative activation of macrophages | |
| Dahbash et al. | The histone deacetylase inhibitor AN7, attenuates choroidal neovascularization in a mouse model |